Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study
Ramón García‐Sánz, Roger G. Owen, Wojciech Jurczak, Meletios A Dimopoulos, Helen O. McCarthy, Gavin Cull, Stephen Opat, Jorge J. Castillo, Marie José Kersten, Björn E. Wahlin, Sebastian Grosicki, Radha Prathikanti, Tian Tian, Heather Allewelt, Aileen Cohen, Constantine S. Tam (2025). Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study. , 9(24), DOI: https://doi.org/10.1182/bloodadvances.2024015596.
Article38 days agoLong-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)
Judith Trotman, Katherine Rankin, Ibrahim Tohidi‐Esfahani, Alessandra Tedeschi, Constantine S. Tam, Christian Buske, Roger G. Owen, Véronique Leblond, Meletios A Dimopoulos, Philip M. Smallwood, Heather Allewelt, Wai‐Yee Chan, Radha Prathikanti, Jingjing Schneider, Remus Vezan, Stephen Opat (2024). Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM). , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-200334.
Article38 days agoPeripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
Benjamin Heyman, Stephen Opat, Björn E. Wahlin, Meletios A Dimopoulos, Jorge J. Castillo, Alessandra Tedeschi, Constantine S. Tam, Christian Buske, Roger G. Owen, Véronique Leblond, Judith Trotman, Gisoo Barnes, Wai‐Yee Chan, Jingjing Schneider, Heather Allewelt, Aileen Cleary Cohen, Jeffrey Matous (2024). Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia. , 9(4), DOI: https://doi.org/10.1182/bloodadvances.2024014115.
Article38 days agoBiomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
Constantine S. Tam, Stephen Opat, Shirley D’Sa, Wojciech Jurczak, Hui‐Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramón García‐Sánz, Helen O. McCarthy, Stephen P. Mulligan, Alessandra Tedeschi, Jorge J. Castillo, Jarosław Czyż, Carlos Fernández de Larrea, David Belada, Edward N. Libby, Jeffrey Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trněný, Monique C. Minnema, Christian Buske, Véronique Leblond, Steven P. Treon, Judith Trotman, Binghao Wu, Yiling Yu, Zhirong Shen, Wai‐Yee Chan, Jingjing Schneider, Heather Allewelt, Aileen Cohen, Meletios A Dimopoulos (2024). Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia. , 8(7), DOI: https://doi.org/10.1182/bloodadvances.2023010906.
Article38 days agoLong-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)
Judith Trotman, Katherine Rankin, Ibrahim Tohidi‐Esfahani, Alessandra Tedeschi, Constantine S. Tam, Christian Buske, Roger G. Owen, Véronique Leblond, Meletios A Dimopoulos, Philip M. Smallwood, Heather Allewelt, Wai‐Yee Chan, Radha Prathikanti, Jingjing Schneider, Remus Vezan, Stephen Opat (2024). Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM). , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-200334.
Article38 days ago